Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Honasa to acquire 58% stake in nutraceutical company Fluence Pharma
Honasa, which sells brands like Mamaearth and Aqualogica, will acquire the stake in two tranches over the next 5–7 years at a pre-aligned valuation construct
Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence Pharma
Honasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry into the health and wellness supplements market. This strategic move aims to leverage Fluence's patented technology and dermatologist network to expand Honasa's 'inside-out' beauty solutions. The acquisition is expected to significantly boost Honasa's growth by diversifying its product portfolio into the rapidly expanding Indian nutraceuticals sector.
Stocks to Watch for June 24: Infosys, IRFC, Honasa Consumer, Delhivery and more
Infosys expands GlobalFoundries AI IT deal, NLC India and IOCL plan green JV, YES Bank, Delhivery, IRFC, Honasa Consumer and Satin Creditcare announce moves. Here are few stocks to track ahead of Wednesday's trading session.
Honasa Consumer to acquire 58% stake in Fluence Pharma for ₹135 crore
Shares of Honasa Consumer Ltd ended at ₹415.90, up by ₹0.85, or 0.20%, on the BSE.
Honasa Consumer’s recovery gains pace. Can execution support its ambitions?
Fresh off an impressive Q4 turnaround, the Mamaearth parent has set its sights on crossing ₹5,000 crore in revenue over the next five years alongside a major margin expansion.
Honasa Consumer shares get an upgrade but target projects downside
HSBC said Honasa now appears to have a more structured strategy for offline expansion, reducing the likelihood of a repeat of the operational challenges it faced during FY25.
Nuvama Gets Market Regulator Nod for Mutual Funds | Honasa Consumer Targets Strong FY31 Growth Outlook | Top Buzzing Stocks Today - Equitymaster
Nuvama Gets Market Regulator Nod for Mutual Funds | Honasa Consumer Targets Strong FY31 Growth Outlook | Top Buzzing Stocks TodayEquitymaster
Nuvama Gets Market Regulator Nod for Mutual Funds | Honasa Consumer Targets Strong FY31 Growth Outlook | Top Buzzing Stocks Today - Equitymaster
Nuvama Gets Market Regulator Nod for Mutual Funds | Honasa Consumer Targets Strong FY31 Growth Outlook | Top Buzzing Stocks TodayEquitymaster
Honasa Consumer, 6 other stocks hit 52-week highs, rally up to 35% in a month
Despite weakness in the broader market, seven BSE 500 stocks including Honasa Consumer, Aegis Logistics and Gland Pharma scaled fresh 52-week highs, gaining up to 35% over the past month amid strong investor buying.
Explained - Why are analysts betting on Honasa Consumer shares to go up to ₹585
Honasa's management, at the company's analyst day, highlighted a strategy centered on faster and more accurate product innovation, enhanced product quality, personalised marketing and wider distribution reach, supported by investments in technology capabilities.
Honasa Consumer jumps 6% to hit 52-week high; is it still worth buying?
Honasa Consumer has shown a strong recovery after testing its all-time low near ₹200 in February 2025, with the stock nearly doubling from those levels
Honasa shares jump 6% on Rs 5,500 crore revenue target by FY31. What is Goldman Sachs saying?
Honasa Consumer shares surged after the company outlined a revenue target of ₹5,500 crore by FY31. The guidance implies an annual growth rate of around 18% between FY26 and FY31. Growth is expected to be led by Mamaearth, with revenue projected to exceed ₹2,000 crore, while The Derma Co is expected to contribute nearly ₹1,500 crore by FY31.